Pancreatic ductal adenocarcinoma (PDAC) is one of the most overlooked cancers despite its
dismal median survival time of 6 months. The biggest challenges in improving patient …

Simple Summary The incidence of pancreatic cancer is increasing but there has been little
progress in the diagnosis and survival rates of this lethal cancer for decades. Understanding …

Background Profound resistance to chemotherapy remains a major challenge in achieving
better clinical outcomes for patients with pancreatic ductal adenocarcinoma (PDAC). Recent …

Background Pancreatic ductal adenocarcinoma is a devastating disease with poor outcome,
generally characterized by an excessive stroma component. The purpose of this study was …

Background Gemcitabine remains a cornerstone in chemotherapy of pancreatic ductal
adenocarcinoma (PDAC) despite suboptimal clinical effects that are partly due to the …

Simple Summary CTHRC1 is a protein with pro-tumoral effects that is highly expressed in
tumors. We found that cancer stroma is the major source of CTHRC1 secretion in pancreatic …

Simple Summary Pancreatic cancer is a devastating disease with a 5-year survival rate of
12%. Only about 20% of patients are candidates for curative surgery, while the majority …

Simple Summary Pancreatic ductal adenocarcinoma (PDAC, also known as pancreatic
cancer) is one of the deadliest tumor types, characterized by poor prognosis, profound …

Pancreatic cancer is associated with highly malignant tumors and poor prognosis due to
strong therapeutic resistance. Accumulating evidence shows that activated pancreatic …

Pancreatic ductal adenocarcinoma (PDAC) is a challenging neoplastic disease, mainly due
to the development of resistance to radio-and chemotherapy. Cold atmospheric plasma …